High Incidence of Amoxicillin-Induced Crystal Nephropathy in Patients Receiving High Dose of Intravenous Amoxicillin.
acute kidney injury
amoxicillin
crystalluria
incidence
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jun 2020
27 Jun 2020
Historique:
received:
31
05
2020
revised:
24
06
2020
accepted:
24
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Amoxicillin (AMX)-induced crystal nephropathy (AICN) is considered as a rare complication of high dose intravenous (IV) AMX administration. However, recently, its incidence seems to be increasing based on French pharmacovigilance centers. Occurrence of AICN has been observed mainly with IV administration of AMX and mostly under doses over 8 g/day. Given that pharmacovigilance data are based on declaration, the real incidence of AICN may be underestimated. Thus, the primary objective of the present study was to determine the incidence of AICN in the current practice. We conducted a retrospective study between 1 January 2015 and 31 December 2017 in Angers University Hospital. Inclusion criteria were age over 18 years-old and IV AMX administration of at least 8 g/day for more than 24 h. Patients admitted directly into the intensive care units were excluded. Medical records of patients that developed Kidney Disease:Improving Global Outcome (KDIGO) stage 2-3 acute kidney injury (AKI) were reviewed by a nephrologist and a specialist in pharmacovigilance. AICN was retained if temporality analysis was conclusive, after exclusion of other causes of AKI, in absence of other nephrotoxic drug administration. A total of 1303 patients received IV AMX for at least 24 h. Among them, 358 (27.5%) were exposed to AMX doses of at least 8 g/day and were included. Patients were predominantly males (68.2%) with a mean age of 69.1 years-old. AMX was administered for a medical reason in 78.5% of cases. Patients received a median dose of AMX of 12 g/day (152.0 mg/kg/day). Seventy-three patients (20.4%) developed AKI, 42 (56.8%) of which were KDIGO stage 2 or 3. Among the latter, AICN diagnosis was retained in 16 (38.1%) patients, representing an incidence of 4.47% of total patients exposed to high IV AMX doses. Only female gender was associated with an increased risk of AICN. AMX dose was not significantly associated with AICN development. This study suggests a high incidence of AICN in patients receiving high IV AMX doses, representing one third of AKI causes in our study. Female gender appeared as the sole risk factor for AICN in this study.
Sections du résumé
BACKGROUND
BACKGROUND
Amoxicillin (AMX)-induced crystal nephropathy (AICN) is considered as a rare complication of high dose intravenous (IV) AMX administration. However, recently, its incidence seems to be increasing based on French pharmacovigilance centers. Occurrence of AICN has been observed mainly with IV administration of AMX and mostly under doses over 8 g/day. Given that pharmacovigilance data are based on declaration, the real incidence of AICN may be underestimated. Thus, the primary objective of the present study was to determine the incidence of AICN in the current practice.
MATERIALS AND METHODS
METHODS
We conducted a retrospective study between 1 January 2015 and 31 December 2017 in Angers University Hospital. Inclusion criteria were age over 18 years-old and IV AMX administration of at least 8 g/day for more than 24 h. Patients admitted directly into the intensive care units were excluded. Medical records of patients that developed Kidney Disease:Improving Global Outcome (KDIGO) stage 2-3 acute kidney injury (AKI) were reviewed by a nephrologist and a specialist in pharmacovigilance. AICN was retained if temporality analysis was conclusive, after exclusion of other causes of AKI, in absence of other nephrotoxic drug administration.
RESULTS
RESULTS
A total of 1303 patients received IV AMX for at least 24 h. Among them, 358 (27.5%) were exposed to AMX doses of at least 8 g/day and were included. Patients were predominantly males (68.2%) with a mean age of 69.1 years-old. AMX was administered for a medical reason in 78.5% of cases. Patients received a median dose of AMX of 12 g/day (152.0 mg/kg/day). Seventy-three patients (20.4%) developed AKI, 42 (56.8%) of which were KDIGO stage 2 or 3. Among the latter, AICN diagnosis was retained in 16 (38.1%) patients, representing an incidence of 4.47% of total patients exposed to high IV AMX doses. Only female gender was associated with an increased risk of AICN. AMX dose was not significantly associated with AICN development.
CONCLUSION
CONCLUSIONS
This study suggests a high incidence of AICN in patients receiving high IV AMX doses, representing one third of AKI causes in our study. Female gender appeared as the sole risk factor for AICN in this study.
Identifiants
pubmed: 32605085
pii: jcm9072022
doi: 10.3390/jcm9072022
pmc: PMC7409099
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3248
pubmed: 26926627
Eur J Nucl Med. 1991;18(5):339-45
pubmed: 1936042
Mo Med. 1999 Jun;96(6):209-11
pubmed: 10405561
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263078
Lancet. 2015 Jun 6;385(9984):2296
pubmed: 25680270
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Lancet. 1993 Sep 11;342(8872):658-61
pubmed: 8103150
Clin J Am Soc Nephrol. 2013 Mar;8(3):476-83
pubmed: 23471414
Br J Clin Pharmacol. 1985 Feb;19(2):191-201
pubmed: 3986077
Drug Saf. 2009;32(1):19-31
pubmed: 19132802
Drugs. 2018 Feb;78(2):163-201
pubmed: 29264783
Nephrol Dial Transplant. 2003 Jan;18(1):212-4
pubmed: 12480988
Kidney Int. 2012 Sep;82(5):516-24
pubmed: 22673882
Endocr Rev. 2013 Aug;34(4):463-500
pubmed: 23550081
Clin Nephrol. 2003 Jun;59(6):455-7
pubmed: 12834178
Expert Opin Drug Saf. 2008 Mar;7(2):147-58
pubmed: 18324877
Kidney Int. 2010 Jun;77(11):956-61
pubmed: 20336051
Eur J Case Rep Intern Med. 2017 Oct 23;4(10):000736
pubmed: 30755915
Nephrol Dial Transplant. 2003 Aug;18(8):1660-2
pubmed: 12897111
Eur Heart J. 2004 Feb;25(3):267-76
pubmed: 14972429
J Am Soc Nephrol. 2017 Jan;28(1):377-387
pubmed: 27297949
Am J Kidney Dis. 2005 May;45(5):804-17
pubmed: 15861345
Eur Heart J. 2009 Oct;30(19):2369-413
pubmed: 19713420
Rambam Maimonides Med J. 2011 Oct 31;2(4):e0061
pubmed: 23908819
Kidney Int. 2014 Nov;86(5):1065-6
pubmed: 25360508
Br J Clin Pharmacol. 2020 Apr 30;:
pubmed: 32353167